CD19 chimeric antigen receptor (CAR) T-cell (CAR-T) therapy tisagenlecleucel (Kymriah®) appeared safe and showed clinical activity in patients with secondary central nervous system (CNS) lymphoma, according to a retrospective cohort analysis of a small group of patients who were treated at a single institution. The findings were published online July 18, 2019 in Blood.

Currently, Kymriah is indicated for patients with relapsed or refractory large B-cell lymphoma, and the drug label explicitly excludes patients with primary CNS lymphoma from the indication. Patients with secondary CNS lymphoma, however, are not explicitly excluded.

Related Articles

The cohort consisted of 8 patients who had high-grade B-cell lymphoma with secondary CNS involvement and were treated with tisagenlecleucel at Massachusetts General Hospital, Boston, between August 2018 and March 2019. Patients were heavily pretreated, having had a median of 5 prior therapies (range, 3-6).

Neurotoxicity higher than grade 1 was not observed in any of the patients; in addition, neither tocilizumab nor steroids were needed to manage toxicity related to CAR-T in any of the patients.

At 28 days after CAR-T infusion, 1 patient had a complete response (CR) with an ongoing response at 90 days. A second patient initially had a CR at 28 days, followed by a systemic relapse at 90 days. One patient initially had a partial response (PR) at 28 days and then achieved a CR at 180 days. A different patient achieved a PR at 28 days and maintained that response at 90 days.

“Our findings suggest that the use of commercial tisagenlecleucel CAR-T for isolated secondary CNS lymphoma may be a viable treatment option for this otherwise challenging patient population,” the study authors wrote. “Due to these promising results we plan to proceed with a pilot study of tisagenlecleucel in primary CNS lymphoma this coming year.”

Reference

Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR-T cell therapy in secondary CNS lymphoma [published online July 18, 2019]. Blood. doi: 10.1182/blood.2019001694